Results 281 to 290 of about 215,802 (313)

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell, 2020
Markus Hoffmann, Nadine Krüger, Tobias S Schiergens   +2 more
exaly  

ยาต้านมะเร็งที่มีฤทธิ์ยับยั้งไซคลินดีเพนเดนท์ไคเนส ;Cyclin-dependent kinases inhibitors

ม.ค.-ต.ค., 3, ไทยไภษัชยนิพนธ์
openaire   +1 more source

Chemical Cyclin-Dependent Kinase Inhibitors: Therapeutic Implications

2000
Edward A. Sausville, Adrian M. Senderowicz   +1 more
openaire   +1 more source

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

Cancer Cell, 2019
Andrei V Krivtsov, Jayant Y Gadrey, Charlie Hatton   +2 more
exaly  

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial

Lancet, The, 2007
Vivian Wing Yan Lee, Wai Keung Leung, James Yun Wong Lau   +2 more
exaly  

Evaluating an RSV inhibitor

Nature Reviews Microbiology, 2022
exaly  

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis

Lancet, The, 2020
Mauro Chiarito, Francesco Cannata, Davide Cao   +2 more
exaly  

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Cancer Cell, 2018
Ewa Gogola, Wouter W Wiegant, Daniel J Vis   +2 more
exaly  

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Lancet, The, 2010
Uri Lopatin, Patrick F Smith
exaly